KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Cash from Financing Activities for 9 consecutive years, with $40.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 105.93% year-over-year to $40.0 million, compared with a TTM value of -$2.2 billion through Dec 2025, down 20.1%, and an annual FY2025 reading of -$2.2 billion, down 20.1% over the prior year.
  • Cash from Financing Activities was $40.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from -$453.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $40.0 million in Q4 2025 and bottomed at -$1.7 billion in Q1 2025.
  • Average Cash from Financing Activities over 5 years is -$500.7 million, with a median of -$493.0 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 35400.0% in 2023, then skyrocketed 105.93% in 2025.
  • Year by year, Cash from Financing Activities stood at -$501.0 million in 2021, then crashed by 41.92% to -$711.0 million in 2022, then grew by 18.99% to -$576.0 million in 2023, then decreased by 17.01% to -$674.0 million in 2024, then skyrocketed by 105.93% to $40.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TEVA at $40.0 million in Q4 2025, -$453.0 million in Q3 2025, and $6.0 million in Q2 2025.